Relay Therapeutics (RLAY) Shares Outstanding (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Shares Outstanding (Entity) of $189.2 million for Q1 2026, up 10.98% year-over-year from $170.5 million in Q1 2025, and up 8.82% quarter-over-quarter from $173.9 million in Q4 2025.
Relay Therapeutics (RLAY) Shares Outstanding (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Shares Outstanding (Entity) for 8 consecutive years, with $189.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 10.98% year-over-year to $189.2 million; the TTM figure through Mar 2026 stood at $189.2 million (up 10.98% YoY), while the FY2025 annual figure was $173.9 million, up 3.64% from the prior year.
- Shares Outstanding (Entity) climbed to $189.2 million in Q1 2026 per RLAY's latest filing, from $173.9 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $189.2 million in Q1 2026 and bottomed at $108.4 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $143.0 million across 5 years, with a median of $132.3 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) gained 1.95% — and 2024, when it surged 35.5%.
- Relay Therapeutics' Shares Outstanding (Entity) stood at $121.1 million in 2022, then advanced by 5.24% to $127.5 million in 2023, then surged by 31.61% to $167.8 million in 2024, then increased by 3.64% to $173.9 million in 2025, then advanced by 8.82% to $189.2 million in 2026.
- Business Quant data shows RLAY's Shares Outstanding (Entity) at $189.2 million in Q1 2026, $173.9 million in Q4 2025, and $172.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 202.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 202.85 Mn |
| Mar 31, 2026 | 179.85 Mn |
| Dec 31, 2025 | 171.59 Mn |
| Sep 30, 2025 | 172.39 Mn |
| Jun 30, 2025 | 171.26 Mn |
| Mar 31, 2025 | 169.23 Mn |
| Dec 31, 2024 | 142.87 Mn |
| Sep 30, 2024 | 140.23 Mn |
| Jun 30, 2024 | 132.82 Mn |
| Mar 31, 2024 | 130.84 Mn |
| Dec 31, 2023 | 122.58 Mn |
| Sep 30, 2023 | 122.23 Mn |
| Jun 30, 2023 | 121.68 Mn |
| Mar 31, 2023 | 121.32 Mn |
| Dec 31, 2022 | 112.23 Mn |
| Sep 30, 2022 | 110.91 Mn |
| Jun 30, 2022 | 108.64 Mn |
| Mar 31, 2022 | 108.29 Mn |
| Dec 31, 2021 | 95.14 Mn |
| Sep 30, 2021 | 92.69 Mn |